Senesco Technologies, Inc. (SNT) Announces Presentation On The Effectiveness Of eIF5A In Inhibiting Tumor Progression In Liver Cancer Models
4/28/2014 9:05:35 AM
Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB:SNTI), announced today that an oral presentation will be delivered on its potential approach to treating hepatocellular carcinoma at the 17th Annual Meeting of the American Society of Gene & Cell Therapy during the session entitled “Cancer-Targeted Gene & Cell Therapy II”.
Help employers find you! Check out all the jobs and post your resume.
comments powered by